{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["077f0780-54d2-4dfd-90de-86f34aea8a8f", "Q2", 400531586, "CROSSROADS STRATEGIES, LLC", 56149, "VERTEX PHARMACEUTICALS INCORPORATED", 2025, "second_quarter", "2025-07-19T13:09:11-04:00", 30000.0, 0, 0, 0, "{\"url\": \"https://lda.gov/api/v1/filings/077f0780-54d2-4dfd-90de-86f34aea8a8f/\", \"filing_uuid\": \"077f0780-54d2-4dfd-90de-86f34aea8a8f\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2025, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.gov/filings/public/filing/077f0780-54d2-4dfd-90de-86f34aea8a8f/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"30000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Mathew Lapinski\", \"dt_posted\": \"2025-07-19T13:09:11-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"800 North Capitol Street, NW, Suite 800\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20002\", \"registrant\": {\"id\": 400531586, \"url\": \"https://lda.gov/api/v1/registrants/400531586/\", \"house_registrant_id\": null, \"name\": \"CROSSROADS STRATEGIES, LLC\", \"description\": \"lobbying firm\", \"address_1\": \"800 North Capitol Street, NW, Suite 800\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20002\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"MATHEW LAPINSKI\", \"contact_telephone\": \"+1 202-559-0170\", \"dt_updated\": \"2026-01-30T13:29:06.487633-05:00\"}, \"client\": {\"id\": 56149, \"url\": \"https://lda.gov/api/v1/clients/56149/\", \"client_id\": 56149, \"name\": \"VERTEX PHARMACEUTICALS INCORPORATED\", \"general_description\": \"biopharmaceutical company\", \"client_government_entity\": null, \"client_self_select\": false, \"state\": \"MA\", \"state_display\": \"Massachusetts\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"MA\", \"ppb_state_display\": \"Massachusetts\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2023-06-01\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 143773, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"CHERYL\", \"nickname\": null, \"middle_name\": \"LYNN\", \"last_name\": \"JAEGER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 66496, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JASON\", \"nickname\": null, \"middle_name\": \"BENJAMIN\", \"last_name\": \"VAN PELT\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 107303, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRITTANY\", \"nickname\": null, \"middle_name\": \"JOHNSON\", \"last_name\": \"HERNANDEZ\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 58561, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MATHEW\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"LAPINSKI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 151117, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"STEPHEN\", \"nickname\": null, \"middle_name\": \"THOMAS\", \"last_name\": \"VOLJAVEC\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Legislative Director, Rep. Vern Buchanan; Legislative Assistant, Senator Marsha Blackburn\", \"new\": true}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MED\", \"general_issue_code_display\": \"Medical/Disease Research/Clinical Labs\", \"description\": \"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 143773, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"CHERYL\", \"nickname\": null, \"middle_name\": \"LYNN\", \"last_name\": \"JAEGER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 66496, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JASON\", \"nickname\": null, \"middle_name\": \"BENJAMIN\", \"last_name\": \"VAN PELT\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 107303, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRITTANY\", \"nickname\": null, \"middle_name\": \"JOHNSON\", \"last_name\": \"HERNANDEZ\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 58561, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MATHEW\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"LAPINSKI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 151117, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"STEPHEN\", \"nickname\": null, \"middle_name\": \"THOMAS\", \"last_name\": \"VOLJAVEC\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Legislative Director, Rep. Vern Buchanan; Legislative Assistant, Senator Marsha Blackburn\", \"new\": true}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 143773, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"CHERYL\", \"nickname\": null, \"middle_name\": \"LYNN\", \"last_name\": \"JAEGER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 66496, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JASON\", \"nickname\": null, \"middle_name\": \"BENJAMIN\", \"last_name\": \"VAN PELT\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 107303, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"BRITTANY\", \"nickname\": null, \"middle_name\": \"JOHNSON\", \"last_name\": \"HERNANDEZ\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 58561, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MATHEW\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"LAPINSKI\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 151117, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"STEPHEN\", \"nickname\": null, \"middle_name\": \"THOMAS\", \"last_name\": \"VOLJAVEC\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Legislative Director, Rep. Vern Buchanan; Legislative Assistant, Senator Marsha Blackburn\", \"new\": true}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}", "DC", "US", null, "MA", "MA", "US", "US", "biopharmaceutical company", null, 0, 2067154, null, "normalized_name_state", 0.9]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json", "registrant_state", "registrant_country", "registrant_house_id", "client_state", "client_ppb_state", "client_country", "client_ppb_country", "client_general_description", "client_government_entity", "affiliated_org_count", "client_entity_id", "client_government_unit_id", "client_match_method", "client_match_confidence"], "primary_keys": ["filing_uuid"], "primary_key_values": ["077f0780-54d2-4dfd-90de-86f34aea8a8f"], "units": {}, "query_ms": 53.266702001565136, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}